Modality
Gene Editing
MOA
AHRant
Target
DLL3
Pathway
Lipid Met
EoENASH
Development Pipeline
Preclinical
~Jun 2012
→ ~Sep 2013
Phase 1
~Dec 2013
→ ~Mar 2015
Phase 2
~Jun 2015
→ ~Sep 2016
Phase 3
~Dec 2016
→ ~Mar 2018
NDA/BLA
Jun 2018
→ Jan 2029
NDA/BLACurrent
NCT06952577
1,384 pts·NASH
2018-06→2029-01·Recruiting
1,384 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-01-212.8y awayPh3 Readout· NASH
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2029-01-21 · 2.8y away
NASH
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06952577 | NDA/BLA | NASH | Recruiting | 1384 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| BII-5449 | Biogen | Phase 3 | FXIa | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| Elratapinarof | Halozyme | Phase 2 | C5 |